Mendus AB (IMMUN)

Currency in SEK
3.775
-0.220(-5.51%)
Real-time Data·
Unusual trading volume
Trading near 52-week Low
IMMUN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.7704.025
52 wk Range
3.7708.490
Key Statistics
Prev. Close
3.995
Open
4.025
Day's Range
3.77-4.025
52 wk Range
3.77-8.49
Volume
63.09K
Average Volume (3m)
29.55K
1-Year Change
-33.3039%
Book Value / Share
8.16
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMMUN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
33.450
Upside
+786.09%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Mendus AB News & Analysis

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 33.450
(+786.09% Upside)

Mendus AB Earnings Call Summary for Q3/2026

  • Mendus posted Q3 2026 operating loss of SEK 21M with zero revenue; cash position at SEK 55.7M, runway extended to Q2 2027 via SEK 46.5M Fenja loan.
  • Year-to-date cash burn improved 12.2% to SEK 56.4M from SEK 64.3M; stock declined 3.92% to $4.78, near lower end of 52-week range.
  • Company completed safety stage of VITAL-CML trial, its first chronic myeloid leukemia study, targeting patients on long-term tyrosine kinase inhibitors.
  • Multiple 2027 catalysts expected: VITAL-CML top-line data mid-year, CADENCE first readout H1, DIVA safety data H1 and efficacy H2.
  • CEO Manting emphasized pursuit of 'functional cure' in CML; company expanding manufacturing with NorthX and planning pediatric AML program with MD Anderson.
Last Updated: 11/11/2026, 09:36 PM
Read Full Transcript

Earnings

Latest Release
Nov 11, 2026
EPS / Forecast
-0.35 / -0.48
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMMUN Income Statement

Compare IMMUN to Peers and Sector

Metrics to compare
IMMUN
Peers
Sector
Relationship
P/E Ratio
−2.4x−2.8x−0.2x
PEG Ratio
−0.17−0.380.00
Price/Book
0.5x10.2x2.6x
Price / LTM Sales
-142.6x2.7x
Upside (Analyst Target)
-0.0%66.0%
Fair Value Upside
Unlock17.7%10.8%Unlock

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company’s lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
47.22M73.65%188.66M
Public Companies & Retail Investors
16.89M26.35%67.48M
Total
64.11M100.00%256.14M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Van Herk Investments B.V.34.88%22,360,17689,329
Flerie AB (publ)22.06%14,145,24256,510

FAQ

What Is the Mendus AB (IMMUN) Stock Price Today?

The Mendus AB stock price today is 3.775 SEK.

What Stock Exchange Does Mendus AB Trade On?

Mendus AB is listed and trades on the Stockholm Stock Exchange.

What Is the Stock Symbol for Mendus AB?

The stock symbol for Mendus AB is "IMMUN."

What Is the Mendus AB Market Cap?

As of today, Mendus AB market cap is 242.030M SEK.

What Is Mendus AB's Earnings Per Share (TTM)?

The Mendus AB EPS (TTM) is -1.73.

When Is the Next Mendus AB Earnings Date?

Mendus AB will release its next earnings report on Feb 11, 2027.

From a Technical Analysis Perspective, Is IMMUN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Mendus AB Stock Split?

Mendus AB has split 4 times.

How Many Employees Does Mendus AB Have?

Mendus AB has 19 employees.

What is the current trading status of Mendus AB (IMMUN)?

As of Nov 17, 2026, Mendus AB (IMMUN) is trading at a price of 3.775 SEK, with a previous close of 3.995 SEK. The stock has fluctuated within a day range of 3.770 SEK to 4.025 SEK, while its 52-week range spans from 3.770 SEK to 8.490 SEK.

What Is Mendus AB (IMMUN) Price Target According to Analysts?

The average 12-month price target for Mendus AB is 33.450 SEK, with a high estimate of 50 SEK and a low estimate of 16.9 SEK. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +786.09% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.